OTCPK:ENSCW (USA)
Â
Warrants (05/12/2019)
$
0.0023
-0.00023 (-9.2%)
10:23 AM EST
Business Description
Ensysce Biosciences Inc
NAICS : 325412
SIC : 2834
ISIN : US2936021169
Share Class Description:
ENSCW: Warrants (05/12/2019)Total Employee Number:
10Description
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 3.03 | |||||
Equity-to-Asset | -0.16 | |||||
Debt-to-Equity | -0.72 | |||||
Debt-to-EBITDA | -0.02 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 87.4 | |||||
3-Year EPS without NRI Growth Rate | 87.6 | |||||
3-Year FCF Growth Rate | 87.2 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.71 | |||||
Quick Ratio | 0.71 | |||||
Cash Ratio | 0.26 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -402.8 | |||||
Shareholder Yield % | 0.2 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -560.44 | |||||
ROA % | -256.38 | |||||
ROIC % | -1699.11 | |||||
3-Year ROIIC % | -320.44 | |||||
ROC (Joel Greenblatt) % | -9645.9 | |||||
ROCE % | -653.71 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | N/A |
N/A
|
N/A
| |||
PE Ratio without NRI | N/A |
N/A
|
N/A
| |||
FCF Yield % | -147800 |
GF Valueâ„¢
Ensysce Biosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ensysce Biosciences Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-12-23 09:00 | In 180 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 139 days | ||
| Second quarter earnings results for 2026 | 2026-08-13 | In 47 days | ||
| First quarter earnings results for 2026 | 2026-05-15 | -- | ||
| First-ever European Pain Therapeutics Summit | 2026-05-07 | -- | ||
| Annual report for 2025 | 2026-03-30 | -- | ||
| Fourth quarter earnings results for 2025 | 2026-03-30 | -- | ||
| General meeting for 2025 | 2025-12-23 09:00 | -- | ||
| Third quarter earnings results for 2025 | 2025-11-14 | -- | ||
| Second quarter earnings results for 2025 | 2025-08-13 | -- |
Show
Entries
Guru Commentaries on OTCPK:ENSCW
No articles.
Press Release
Articles on Ensysce Biosciences Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers